Cargando…

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan

Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamana, Yoichiro, Kanda, Tatsuo, Matsumoto, Naoki, Honda, Masayuki, Kumagawa, Mariko, Sasaki, Reina, Kanezawa, Shini, Mizutani, Taku, Yamagami, Hiroaki, Masuzaki, Ryota, Ishii, Tomotaka, Nirei, Kazushige, Moriyama, Mitsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658140/
https://www.ncbi.nlm.nih.gov/pubmed/34884231
http://dx.doi.org/10.3390/jcm10235529
_version_ 1784612659733200896
author Yamana, Yoichiro
Kanda, Tatsuo
Matsumoto, Naoki
Honda, Masayuki
Kumagawa, Mariko
Sasaki, Reina
Kanezawa, Shini
Mizutani, Taku
Yamagami, Hiroaki
Masuzaki, Ryota
Ishii, Tomotaka
Nirei, Kazushige
Moriyama, Mitsuhiko
author_facet Yamana, Yoichiro
Kanda, Tatsuo
Matsumoto, Naoki
Honda, Masayuki
Kumagawa, Mariko
Sasaki, Reina
Kanezawa, Shini
Mizutani, Taku
Yamagami, Hiroaki
Masuzaki, Ryota
Ishii, Tomotaka
Nirei, Kazushige
Moriyama, Mitsuhiko
author_sort Yamana, Yoichiro
collection PubMed
description Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of Tokyo, Japan. Although 106 patients were consecutively included, a total of 102 HCV-infected patients with chronic hepatitis or compensated cirrhosis, who received 8- or 12-week combination treatment with glecaprevir/pibrentasvir and were followed up to week 12 after the end of treatment were analyzed retrospectively. Only three patients discontinued treatment due to adverse events; however, they achieved a sustained virologic response at 12 weeks (SVR12). Finally, SVR rates were 99.0% (101/102). Only one patient without liver cirrhosis was a treatment relapser who received hepatic resection for HCC approximately two years after commencement of the 8-week combination treatment with glecaprevir/pibrentasvir. After the exclusion of patients with HCV genotype 1b and P32 deletion in the HCV NS5A region, a 12-week combination of glecaprevir/pibrentasvir led to SVR12 in all nine direct-acting antiviral-experienced patients. Glecaprevir/pibrentasvir had a high efficacy and an acceptable safety profile for real-world HCV patients in a single hospital in Japan.
format Online
Article
Text
id pubmed-8658140
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86581402021-12-10 Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan Yamana, Yoichiro Kanda, Tatsuo Matsumoto, Naoki Honda, Masayuki Kumagawa, Mariko Sasaki, Reina Kanezawa, Shini Mizutani, Taku Yamagami, Hiroaki Masuzaki, Ryota Ishii, Tomotaka Nirei, Kazushige Moriyama, Mitsuhiko J Clin Med Article Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of Tokyo, Japan. Although 106 patients were consecutively included, a total of 102 HCV-infected patients with chronic hepatitis or compensated cirrhosis, who received 8- or 12-week combination treatment with glecaprevir/pibrentasvir and were followed up to week 12 after the end of treatment were analyzed retrospectively. Only three patients discontinued treatment due to adverse events; however, they achieved a sustained virologic response at 12 weeks (SVR12). Finally, SVR rates were 99.0% (101/102). Only one patient without liver cirrhosis was a treatment relapser who received hepatic resection for HCC approximately two years after commencement of the 8-week combination treatment with glecaprevir/pibrentasvir. After the exclusion of patients with HCV genotype 1b and P32 deletion in the HCV NS5A region, a 12-week combination of glecaprevir/pibrentasvir led to SVR12 in all nine direct-acting antiviral-experienced patients. Glecaprevir/pibrentasvir had a high efficacy and an acceptable safety profile for real-world HCV patients in a single hospital in Japan. MDPI 2021-11-26 /pmc/articles/PMC8658140/ /pubmed/34884231 http://dx.doi.org/10.3390/jcm10235529 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamana, Yoichiro
Kanda, Tatsuo
Matsumoto, Naoki
Honda, Masayuki
Kumagawa, Mariko
Sasaki, Reina
Kanezawa, Shini
Mizutani, Taku
Yamagami, Hiroaki
Masuzaki, Ryota
Ishii, Tomotaka
Nirei, Kazushige
Moriyama, Mitsuhiko
Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title_full Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title_fullStr Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title_full_unstemmed Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title_short Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
title_sort efficacy of glecaprevir/pibrentasvir for real-world hcv infected patients in the northern part of tokyo, japan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658140/
https://www.ncbi.nlm.nih.gov/pubmed/34884231
http://dx.doi.org/10.3390/jcm10235529
work_keys_str_mv AT yamanayoichiro efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT kandatatsuo efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT matsumotonaoki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT hondamasayuki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT kumagawamariko efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT sasakireina efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT kanezawashini efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT mizutanitaku efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT yamagamihiroaki efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT masuzakiryota efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT ishiitomotaka efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT nireikazushige efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan
AT moriyamamitsuhiko efficacyofglecaprevirpibrentasvirforrealworldhcvinfectedpatientsinthenorthernpartoftokyojapan